Fisher Bros. Sales v. United States

46 F.3d 279, 1995 WL 29865
CourtCourt of Appeals for the Third Circuit
DecidedJanuary 25, 1995
Docket93-1182, 93-1205, 93-1206, 93-1207, 93-1208 and 93-1209
StatusUnknown
Cited by1 cases

This text of 46 F.3d 279 (Fisher Bros. Sales v. United States) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Fisher Bros. Sales v. United States, 46 F.3d 279, 1995 WL 29865 (3d Cir. 1995).

Opinions

Argued Sept. 23, 1993

Before: STAPLETON, ROTH and LEWIS, Circuit Judges. Before: SLOVITER, Chief Judge, BECKER, STAPLETON, MANSMANN, GREENBERG, HUTCHINSON, SCIRICA COWEN, NYGAARD, ALITO, ROTH, LEWIS and McKEE, Circuit Judges.

OPINION OF THE COURT

STAPLETON, Circuit Judge:

The Federal Tort Claims Act (“FTCA”), 28 U.S.C. §§ 1346(b), 2671-2680, waives the federal government’s sovereign immunity with respect to tort claims for money damages. The “discretionary function exception” to the FTCA limits that waiver, stating that the government retains sovereign immunity with respect to “[a]ny claim ... based upon the exercise or performance [of,] or the failure to exercise or perform[,] a discretionary function or duty ..., whether or not the discretion involved be abused.” 28 U.S.C. § 2680(a). The appeals now before the court [282]*282in banc require us to examine the scope of the discretionary function exception.

The plaintiffs in these cases were injured by several policy decisions made by the Commissioner of the Food and Drug Administration (“FDA”) while exercising a discretionary function. They seek to avoid the legal consequences that would flow from application of the discretionary function exception to their cases by (1) looking behind the Commissioner’s injury-causing decision, (2) finding fault with an aspect of the data upon which it may have been based, and (3) arguing that their claims are not “based upon” the Commissioner’s decisions but instead are “based upon” the alleged negligence of various laboratory technicians who supplied the allegedly faulty data to the Commissioner. We reject this attempt to circumvent the discretionary function exception, concluding that if the discretionary function exception to the FTCA is to fulfill its clear and important purpose, a claim must be “based upon” the exercise of a discretionary function whenever the immediate cause of the plaintiffs injury is a decision which is susceptible of policy analysis and which is made by an official legally authorized to make it. Because the plaintiffs’ claims are based upon decisions susceptible of policy analysis and made by an official of the executive branch acting within his authority, we will affirm the district court’s order dismissing these cases for lack of subject-matter jurisdiction.

For the purpose of our analysis, we have assumed the facts alleged by the plaintiffs to be true. Berkovitz v. United States, 486 U.S. 531, 540, 108 S.Ct. 1954, 1960-61, 100 L.Ed.2d 531 (1988). Our “scope of review of the applicability of the discretionary function exception is plenary.” United States Fidelity & Guar. Co. v. United States, 837 F.2d 116, 119 (3d Cir.), cert. denied, 487 U.S. 1235, 108 S.Ct. 2902, 101 L.Ed.2d 935 (1988).

I.

On March 2, 1989, an anonymous caller to the United States Embassy in Santiago, Chile, stated that Chilean fruit bound for the United States would be injected with cyanide. The FDA took the lead agency role in evaluating the seriousness of the call, and it detained all incoming Chilean fruit over the weekend of March 4 and 5 while it undertook an investigation. On March 6, having found no evidence that any Chilean fruit had actually been poisoned, the FDA announced that it considered the call a hoax. It nevertheless continued to conduct experiments concerning the effects that cyanide injections would have on various Chilean fruits.

The embassy in Santiago then received a second anonymous call. This time the warnings were more specific. The caller indicated that he had access to orchards, storage facilities, and shipping locations in Chile, and stated that unidentified fruit had already been injected with cyanide. This prompted the FDA’s Philadelphia District Office to double the inspection level of incoming Chilean fruit, beginning with that arriving on the “Almería Star.” The Philadelphia District Office designated that certain portions of the Almería Star’s cargo would be examined, and any fruit that looked “suspect” was to be sent to the Philadelphia District Office for testing.

The increased level of inspection soon yielded results. On the morning of March 12, an FDA inspector discovered two grapes from the Almería Star which appeared to have been punctured, and which displayed uniform white rings. Further examination of the crate containing these suspect grapes revealed a third white-ringed grape, which, unlike the others, appeared to have been slit rather than punctured. Although the physical appearance of these grapes was inconsistent with that of grapes injected with cyanide during FDA experimentation, the FDA officials as a precautionary measure sent the grapes, as well as the crate in which they were packaged, to the FDA’s Philadelphia laboratory for testing.

The Philadelphia laboratory began testing the grapes for cyanide in the early afternoon of March 12. The FDA technicians used all of the two punctured grapes in conducting their tests, but saved the third, slit, grape for [283]*283confirmation purposes. The testing process required the grapes to be mashed until they turned into a solution. Sulfuric acid was then added to this slurry, causing a chemical reaction that released in gaseous form any cyanide that was present in the solution. The gas released from the solution was twice exposed to cyanide-sensitive strips of reactive paper, both of which indicated the presence of cyanide. A third test then confirmed a high concentration of cyanide present in the slurry. At approximately 9:30 p.m. on March 12, the Philadelphia laboratory orally reported positive cyanide test results from the solution to the FDA’s Emergency Operations Center.

Meanwhile, FDA officials transferred a portion of the slurry, along with the third, slit, grape and the bunch in which these grapes had been found, to the FDA’s Cincinnati laboratory. Technicians there identified two additional white-ringed grapes on the bunch, but were unable to confirm the presence of cyanide. The Philadelphia laboratory also continued testing other grapes from the suspect crate, as well as all packing materials in that crate. These further tests also failed to reveal the presence of cyanide.

The Commissioner was supplied with the findings of the Philadelphia and Cincinnati laboratories in the early morning hours of March 13. The information before him at that point was that three tests conducted on two of the suspect grapes indicated the presence of cyanide. The retesting of the slurry and the testing of the third “reserved” grape, the other grapes, and the packaging, however, did not confirm the presence of cyanide. He also knew of the reports to the embassy in Santiago and the surveillance activity that had already been conducted. On the basis of this information, the Commissioner on March 13 issued an order refusing entry of any additional Chilean fruit into the United States and requiring the withdrawal and destruction of all Chilean fruit then in domestic channels of distribution. The FDA also issued a press release publicizing the Philadelphia laboratory’s finding of cyanide in two Chilean grapes and the order refusing the entry of Chilean fruit into the United States.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
46 F.3d 279, 1995 WL 29865, Counsel Stack Legal Research, https://law.counselstack.com/opinion/fisher-bros-sales-v-united-states-ca3-1995.